RecruitingNot ApplicableNCT07127458

Anxiety and Depression in Adolescent PCOS

Prevalence of Anxiety and Depression in Adolescents With Polycystic Ovary Syndrome

Sponsor

Ege University

Enrollment

42 participants

Start Date

Aug 17, 2025

Study Type

INTERVENTIONAL

Conditions

PCOS (Polycystic Ovary Syndrome)

Summary

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder in adolescent females, often accompanied by psychological symptoms such as anxiety and depression. These conditions are frequently underdiagnosed and untreated. This study aims to determine the prevalence of anxiety and depression in adolescents with PCOS and to assess changes following oral contraceptive use.

Eligibility

Sex: FEMALEMin Age: 15 YearsMax Age: 19 Years

Inclusion Criteria2

Age between 15 and 19 years
Diagnosis of adolescent polycystic ovary syndrome (PCOS)

Exclusion Criteria5

Severe reading or comprehension difficulties
Severe hearing impairment
Current use of hormone therapy
Presence of a virilizing tumor
Major psychiatric disorders such as schizophrenia, bipolar disorder, or dissociative disorder

Interventions

DRUGAdolescent PCOS group receiving oral contraceptives

Participants diagnosed with polycystic ovary syndrome (PCOS) during adolescence will receive a combined oral contraceptive (ethinylestradiol 30 µg + drospirenone 3 mg) once daily for six consecutive months. The intervention aims to regulate menstrual cycles, reduce hyperandrogenic symptoms, and evaluate changes in anxiety and depression scores over time.